The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs and symptoms of blepharitis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~26 days
Sall Research Medical Center
Artesia, California, United States
North Valley Eye Medical Group
Mission Hills, California, United States
Center for Excellence in Eye Care
Miami, Florida, United States
Kentuckiana Institute for Eye Research
change in clinical signs and symptoms associated with blepharitis
Time frame: 4 weeks
standard ocular safety assessments
Time frame: 4 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Louisville, Kentucky, United States
Tauber Eye Center
Kansas City, Missouri, United States
Silverstein Eye Centers
Kansas City, Missouri, United States
South Shore Eye Care, LLP
Wantagh, New York, United States
Toyos Clinic
Jackson, Tennessee, United States
Corona Research Consultants, Inc.
El Paso, Texas, United States